Founded in 1998, Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. The firm prefers to invest in the life science, biotechnology, and oncology sector.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Alterome Therapeutics | 19-Jan-2022 | Early Stage VC | 000.00 | Biotechnology | Startup | 00000 000000000 00.0 |
0000000 0000000000 | 05-Jan-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - General | 0000000 000000000 00.0 |
000 000000000000 | 04-Oct-2021 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 00000 000000000 00.0 |
0000000 000 | 22-Sep-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
0000000 | 28-Jul-2021 | 00000 00000 | 00000 | Drug Discovery | Startup | |
000000 000000 | 16-Jun-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000 000000000 00.0 |
000000000 000 | 04-Jun-2021 | 00000 00000 | 0000 | Drug Discovery | Stealth | 00000 000000000 00.0 |
00000 000000000000 | 13-May-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
Boundless Bio | 28-Apr-2021 | Early Stage VC | 00000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
Tyra Biosciences | 31-Mar-2021 | Early Stage VC | 00000 | Drug Discovery | Pre-Clinical Trials | 0000000 000000000 00.0 |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
EQRx | 17-Dec-2021 | Reverse Merger | 00.00 |
0000 00000000000 | 15-Sep-2021 | 000 | 00000 |
00000000 000000000 | 01-Aug-2021 | 000000000000000000 | 00.00 |
00000000 00000000 | 08-Jan-2021 | 000 | 00000 |
0000000000 0000000 | 04-Dec-2020 | 000 | 00000 |
0000000 000000000 | 03-Dec-2020 | 000 | 00000 |
000000 000 | 09-Oct-2020 | 000 | 00000 |
00 000000000000 | 02-Oct-2020 | 000 | 00000 |
PMV Pharma | 25-Sep-2020 | IPO | 00000 |
Revolution Medicines | 13-Feb-2020 | IPO | 00000 |
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialName | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Marco Weibel | Chief Financial Officer | Zurich, Switzerland | |||
Thomas Lips Ph.D | General Partner | Zurich, Switzerland | |||
Alfred Scheidegger Ph.D | Founder & Partner | 0 | 0 | Zurich, Switzerland | |
Jakob Loven Ph.D | Partner | 00 | 0 | 0 | Zurich, Switzerland |
Rocco Sgobbo | Partner | Zurich, Switzerland |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Boxer Capital | 13 | 0 | 0 |
![]() |
![]() |
Casdin Capital | 00 | 0 | 0 |
![]() |
![]() |
RA Capital Management | 00 | 0 | 00 |
![]() |
![]() |
Logos Capital | 0 | 0 | 0 |
![]() |
![]() |
OrbiMed | 0 | 0 | 0 |
![]() |
![]() |